Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 4/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 4/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564096 | 1.00 | JAK2 (0.42) | JAK2JAK1ABCB1UCHL1NR1H2 | |
| SCHEMBL7859886 | 0.84 | NR1H2 (0.46) | JAK2JAK1ABCB1UCHL1NR1H2 | |
| SCHEMBL30207112 | 0.81 | ABCB1 (0.47) | JAK2JAK1ABCB1UCHL1NR1H2 | |
| SCHEMBL4292542 | 0.81 | ABCB1 (0.47) | JAK2JAK1ABCB1UCHL1NR1H2 | |
| SCHEMBL4298537 | 0.80 | JAK2 (0.43) | JAK2JAK1ABCB1UCHL1NR1H2 | |
| SCHEMBL9611279 | 0.79 | ABCB1 (0.60) | ABCB1PRMT5MEN1KMT2APARP1 | |
| SCHEMBL2707560 | 0.79 | ABCB1 (0.60) | ABCB1PRMT5MEN1KMT2APARP1 | |
| SCHEMBL3948290 | 0.79 | ABCB1 (0.41) | ABCB1UCHL1SRCPRMT5PARP1 | |
| SCHEMBL7862914 | 0.79 | ABCB1 (0.41) | ABCB1UCHL1SRCPRMT5PARP1 | |
| SCHEMBL9138470 | 0.78 | ABCB1 (0.31) | ABCB1UCHL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270379-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270379-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | NQO2, QARS1, NQO1 | JAK2 3899/4885JAK1 3808/4885ABCB1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.